TMSB10 and tuberculosis: Although based on the data presented we cannot conclude about the direct protective contribution of TB10.4 and RpfB-specific immunity alone, the comparison between our Mono., Biv., and Tri:ChAd:TB vectors strongly suggests that expression of additional antigens from the M.tb life cycle and thus, the induction of immunity against these antigens (Fig. 2), directly correlate with enhanced protection, with Tri:ChAd:TB vaccine design providing the best level of protection.